General description

Cardamonin, a known 2′,4′-dihydroxy-6′-methoxychalcone, was recently identified as an inhibitor of melanocyte differentiation, among many other pharmacology activities. Cardamonin promoted degradation of intracellular β-catenin while suppressing melanogenesis by down-regulating the expression of MITF and tyrosinase, resulting in decreased melanin content. Furthermore, it was found that cardamonin promoted the degradation of β-catenin through a GSK-3β-independent mechanism, which suggested that Siah-dependent pathway and/or a PKCa-dependent pathway, rather than a GSK-3&beta:-dependent pathway, may mediate intracellularb-catenin degradation by cardamonin.

Cardamonin, a known 2′,4′-dihydroxy-6′-methoxychalcone, was identified as an inhibitor of melanocyte differentiation, among many other pharmacology activities. Cardamonin promoted degradation of intracellular β-catenin while suppressing melanogenesis by down-regulating the expression of MITF and tyrosinase, resulting in decreased melanin content. Furthermore, it was found that cardamonin promoted the degradation of β-catenin through a GSK-3β-independent mechanism, which suggested that Siah-dependent pathway and/or a PKCA-dependent pathway, rather than a GSK-3β-dependent pathway, may mediate intracellularb-catenin degradation by cardamonin.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Warning

Toxicity: Standard Handling (A)